PFA Pension Forsikringsaktieselskab Makes New $1.92 Million Investment in Exelixis, Inc. $EXEL

PFA Pension Forsikringsaktieselskab acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, Holdings Channel.com reports. The fund acquired 43,658 shares of the biotechnology company’s stock, valued at approximately $1,923,000.

Other hedge funds have also recently modified their holdings of the company. Richardson Financial Services Inc. grew its stake in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC grew its stake in shares of Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of Exelixis during the third quarter valued at approximately $28,000. Activest Wealth Management bought a new position in shares of Exelixis during the fourth quarter valued at approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Exelixis by 1,380.4% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 773 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Up 1.1%

Shares of NASDAQ:EXEL opened at $44.17 on Tuesday. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $49.62. The stock has a market cap of $11.22 billion, a P/E ratio of 15.95, a price-to-earnings-growth ratio of 0.98 and a beta of 0.38. The business’s 50 day moving average is $43.31 and its 200 day moving average is $42.82.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. Exelixis’s revenue was up 5.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Exelixis, Inc. will post 3.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on EXEL. Wells Fargo & Company upped their target price on Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a research note on Monday, January 5th. Wall Street Zen cut Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 18th. Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price on the stock. in a research note on Monday, January 5th. Finally, Morgan Stanley upped their target price on Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $47.00.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 99,574 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the transaction, the director owned 279,942 shares of the company’s stock, valued at $12,320,247.42. This represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher J. Senner sold 34,278 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the transaction, the chief financial officer directly owned 1,042,579 shares in the company, valued at approximately $44,830,897. This trade represents a 3.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 362,849 shares of company stock valued at $15,917,463 over the last 90 days. 2.60% of the stock is owned by insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.